Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Open House Drug Discount Contracts Interferon Beta1a, Finished Medicinal Product Designation Avonex(r), Atc L03ab07 2028-04-03
Germany Open Framework Agreement For Pharmaceutical Discounts In Accordance With § 130a Abs.8 Sgb V With The Possibility Of Joining At Any Time, Known As The Admission Model 2026-05. Pharmaceutical Discounts 2028-04-05
Germany Open Framework Agreement On Pharmaceutical Discounts According To § 130a Para. 8 Sgb V With The Possibility Of Joining At Any Time, So-called Approval Model 202605 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Tiotropium + Olodaterol For The Period From 01.06.2026 To 31.05.2028. Tiotropium, Olodaterol 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Betamethasone + Calcipotriol (exclusively In The Dafo Foam), Atc D05ax22 For The Period June 1st, 2026 - May 31st, 2028 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Roxadustat For The Period From 01.06.2026 To 31.05.2028. Roxadustat 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Trastuzumab (exclusively 600 Mg I.e.d.), Atc L01fd01 For The Period June 1, 2026 - May 31, 2028 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Dolutegravir, Atc J05aj03 For The Period June 1st, 2026 - May 31st, 2028 2028-04-05
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Daridorexant For The Period From 01.06.2026 To 31.05.2028. Daridorexant 2028-04-05
Germany The Dak-gesundheit Intends To Conclude A Non-exclusive Discount Agreement For The Active Ingredient Roxadustat, Atc B03xa05, For The Period From June 1, 2026, To May 31, 2028. This Agreement Allows Health Insurance Companies And Pharmaceutical Companies T 2028-04-05
Whats app